Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
2006 Oct;46(1):23-8
doi: 10.1016/j.freeradbiomed.2013.07.036 115
These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
Enter orforglipron , the latest contender in the nonpeptide small molecule class, which promises the benefits of GLPs without the injection or the fuss
doi: 10.1002/art.22854 124 VierboomMPZavodnyPJChouCCTagatJRPugliese-SivoCStrizkiJet al
US$ 23.55
US$ 23.37
US$ 24.29
US$ 20.05
US$ 24.83
